葛兰素史克Glaxosmithkline plc (GSK) 2016年年度报告「LSE」.pdf

1、Annual Report 20162016 saw good sales momentum across Pharmaceuticals,Vaccines and Consumer Healthcare and further pipeline progressCautionary statement regarding forward-looking statementsThe Groups reports filed with or furnished to the US Securities and Exchange Commission(SEC),including this doc

2、ument and written information released,or oral statements made,to the public in the future by or on behalf of the Group,may contain forward-looking statements.Forward-looking statements give the Groups current expectations or forecasts of future events.An investor can identify these statements by th

3、e fact that they do not relate strictly to historical or current facts.They use words such as anticipate,estimate,expect,intend,will,project,plan,believe and other words and terms of similar meaning in connection with any discussion of future operating or financial performance.In particular,these in

4、clude statements relating to future actions,prospective products or product approvals,future performance or results of current and anticipated products,sales efforts,expenses,the outcome of contingencies such as legal proceedings,and financial results.Other than in accordance with its legal or regul

5、atory obligations(including under the UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority),the Group undertakes no obligation to update any forward-looking statements,whether as a result of new information,future events or otherwise.The reader should,however

6、,consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the SEC.All readers,wherever located,should take note of these disclosures.Accordingly,no assurance can be given that any particular expectation will be met and shareholders and investor